Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet

On August 26, Biohaven announced a global licensing agreement with SK Biopharmaceuticals covering opakalim, the company’s primary epilepsy candidate. The transaction included up to $795 million in upfront and milestone payments along with tiered royalties, with Biohaven receiving $350 million at closing and an additional $50 million scheduled for 2027, plus potential milestone and royalty payments reaching $150 million or more.
The timing of the agreement aligned with Biohaven’s Aug